Thread by @GuyKatzMD

So many amazing teams, having trouble filling out my #RheumMadness bracket!

2021: I thought the tournament came down to clinical trials vs scientific discoveries

https://twitter.com/GuyKatzMD/status/1374918372228530176?s=20&t=1LUEiGAQ9Eh9jD5wV5YTcQ

Spoiler alert: clinical trials won (😢)

2022: past vs present vs future?

🧵

Cells region: all about future implication
- NET: hot topic for a while now, but not yet ready for clinical utility
- Cytokine networks: may redefine how we classify rheumatic disease, though not anytime soon

CAR-T and Pim kinases: both cancer therapies that can be repurposed for rheumatic disease

Both many years away from routine clinical care, though CAR-T has been successful in severe SLE!

Animals region: bridging past and future
- Do ancient evolutionary advances (axolotl limbs) have a role in regenerative medicine?
- Do dinosaur skeletons teach us about SpA today?
- Can we improve human tx by studying dog physiology that has been around forever (gout, OA)?

Machines region:
- Predicting TNFi response, JIA subtypes: discovering new ways to use tech in rheum in future, but far from clinical utility
- DECT, PET in LVV: how to optimize tech already at our disposal for dx and monitoring in challenging cases

People region: all about NOW
- Repro health guide, TNFi in cord blood: how can we care for pregnant rheumatic disease patients better now?
- How do we interpret tests we already use all the time (ANA, MRI)?

Ultimately, this comes down to the #BlueRibbonPanel
❓Will they prioritize current clinical utility?
❓Will they take into consideration the historical context of current discoveries?
❓For future implications, is it about magnitude of impact or time to clinical applicability?

Any thoughts on how the Blue Ribbon Panel will decide?

Anyone willing to share their predictions/reasoning?

@DavidLeverenz @Nephro_Sparks @LisaCriscione @AUGarren